Table 3.

Most frequent relevant pharmacological interactions in patients who received inducers and/or inhibitors of cytochrome P450 in Colombia

Interactions	n	%a	Prevalenceb
Major	18,679	100.0	12.2
Fluconazole—Metronidazole	1661	8.9	1.1
Fluconazole—Atorvastatin	1467	7.9	1.0
Amiodarone—Carvedilol	1146	6.1	0.7
Diltiazem—Atorvastatin	808	4.3	0.5
Carbamazepine—Sertraline	735	3.9	0.5
Carbamazepine—Tramadol	701	3.8	0.5
Carbamazepine—Quetiapine	683	3.7	0.4
Carbamazepine—Trazodone	649	3.5	0.4
Carbamazepine—Codeine	603	3.2	0.4
Carbamazepine—Fluoxetine	490	2.6	0.3
Carbamazepine—Clonazepam	489	2.6	0.3
Carbamazepine—Nimodipine	458	2.5	0.3
Carbamazepine—Linagliptin	448	2.4	0.3
Fluconazole—Ciprofloxacin	435	2.3	0.3
Carbamazepine—Dexamethasone	420	2.2	0.3
Contraindicated	821	100.0	0.5
Fluconazole—Trazodone	167	20.3	0.1
Fluconazole—Ketoconazole	135	16.4	0.1
Fluconazole—Quetiapine	123	15.0	0.1
Verapamil—Colchicine	76	9.3	<0.1
Clarithromycin—Colchicine	35	4.3	<0.1
Ketoconazole—Ergotamine	33	4.0	<0.1
Amiodarone—Colchicine	29	3.5	<0.1
Ketoconazole—Nimodipine	26	3.2	<0.1
Fluconazole—Domperidone	21	2.6	<0.1
Clarithromycin—Fluconazole	15	1.8	<0.1
Fluconazole—Clozapine	15	1.8	<0.1
Ketoconazole—Trazodone	13	1.6	<0.1
Diltiazem—Colchicine	10	1.2	<0.1
Fluconazole—Mirtazapine	9	1.1	<0.1
Ketoconazole—Colchicine	9	1.1	<0.1

^aPercentage calculated on the number of patients with major or contraindicated interactions

^bPrevalence per 1000 people with medication dispensing